My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  collaboration  alliances  partnering  alliance  alliance managers  partners  alliance manager  partner  partnerships  ecosystem  The Rhythm of Business  governance  Jan Twombly  partnership  Strategic Alliance Magazine  Eli Lilly and Company  IoT  Vantage Partners  biopharma  Healthcare  NetApp  2015 ASAP Global Alliance Summit  ASAP BioPharma Conference  Cisco  IBM  innovation  strategy  Christine Carberry  communication 

Lilly and WuXi App Tech: Tips and Insights from a Successful Western and Chinese Pharmaceutical Collaboration

Posted By Cynthia B. Hanson, Friday, September 9, 2016

Only 50 percent of China’s population is urbanized, which means the pace of change over the next decade is likely to be colossal. Its already one of the largest and fastest growing pharmaceutical markets. But it also can be one of the most challenging for alliance managers to negotiate because of the cultural differences. 

Eli Lilly and Company is known for being one of the firstand most persistentpharmaceuticals to make inroads into China. The company began with an R&D partnership with Shanghai-based WuXi App Tech in 2003. Last year, the companies entered into a significant strategic collaboration for a new project as part of a global program. 

For Brent Harvey, CA-AM, director of alliances at Lilly, the test tube is clearly more than half-full when it comes to doing business in China. “How do we leverage the difference between our two companies or cultures for competitive advantage?” he asked during the session “A New Model for Western and Chinese Pharmaceutical Partnering,” at the 2016 ASAP BioPharma Conference “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed” held Sept. 7-9 at the Revere Hotel Boston Common, Boston. 

Assisting with the presentation was Zhihui Qiu, Director of Strategic Transactions, at WuXi App Tech (Shanghai) Co., who shared her company’s perspective. The two company representatives discussed their approach to resolve cultural differences, cut government red tape, and extract long-term value from the partnership. They provided several valuable tips gleaned from the experience: 

IP Security
Harvey: We typically manage the IP at the mother ship. But we also have local counsel. It is so hard to keep track of what’s going on there, so it’s important to have that local presence. 

Qiu: IP is receiving increasing attention in China. Dedicated IP Courts were established in China earlier this year. In the United States, you tend to have very good IP management. In China, it is not a big practice yet. You probably need local help and US counsel to work together to make sure you are protected. 

Contracts

Harvey: We try to de-risk as much as we can in the contract. We tend to view it as definitive, while the Chinese view it as general guideline. When I think about Western trust, it’s someone who honors his or her word. In China, this perspective is about honing change in mutualities. Chinese people want to stay practical. They don’t want to rewrite their contact. 

Qiu:  Contacts tend to be simple and boilerplates are greatly simplified. As the relationship evolves, the contract may be replaced by a new one to better serve the purpose. 

Making the Deal

Harvey: It’s very important to have high-profile executives helping to build trust and social capital. In Western culture, the deal is the deal, and we would probably celebrate it by going to a bar. 

Qiu: We might celebrate the major deals with a ceremony. The government is trying to foster and build innovation in pharma industry, and we would invite multiple government officials and key opinion leaders to the ceremony to raise their awareness. 

Planning and Team Meetings

Harvey: Time zone differences can be challenging; use a lunar calendar because holidays will change. It’s very important to have actions and decisions clearly documented in meeting minutes. The Chinese have a different approach to planning with optimistic and aggressive milestone dates. It has benefitted Lilly to be stretched and pushed by aggressive Chinese firms. Relationships are important, but there is a lot of turnover in Chinese firms, which is something you should be aware of going in. 

Qiu: Chinese company power is more centralized, which allows the Chinese to push. Our teams are Western educated; the English is really good, which helps a lot with communications. You won’t need translators. Face-to-face meetings are important. 

Regulatory pathways

Harvey: China issued a new policy to allow biotech companies to hold product licenses. Manufacturers used to be the only ones who could hold the license. Things change so quickly in China, and you need to think about how you are staffing your alliances to be agile and adaptable in this very, very dynamic environment.

Qiu: New drugs used to be produced by the multinationals, and domestic companies didn’t have the capability for innovation, but that has changed in the last 10 years. A government agency set prices incentives for innovative drugs developed by domestic companies. 

Government Regulation

Harvey: It took a lot of conversation, the documents were in Chinese, and requirements needed transcription. It took a lot to engage the expertise of Lilly’s Shanghai and Beijing offices. It was not easy to figure out what we needed to do to have an acceptable package. 

Qiu: You need local people who truly understand regulatory affairs in China. Your approach depends on what route you are going and the specific goals you are trying to achieve. 

Tags:  ASAP BioPharma Conference  Brent Harvey  contracts  cultural differences  cultures  Eli Lilly and Company  Government Regulation  high-profile executives  IP Security  partnership  pharmaceuticals  Planning and Team Meetings  R&D partnership  Regulatory pathways  strategic transactions  WuXi App Tech  Zhihui Qiu 

Share |
PermalinkComments (0)
 

Ben Gomes-Casseres and the Bayer Team Return to the 2016 ASAP BioPharma Conference with an Interactive Roundtable on Creating Alliance Success

Posted By Cynthia B. Hanson, Tuesday, September 6, 2016

One session at last year’s ASAP BioPharma Conference was such a success that Ben Gomes-Casseres, CSAP, DBA, and the Bayer HealthCare team are returning with the same theme in a new interactive roundtable format. Their deep dive on “Making Better Alliances: How Alliance Management, Business Development, and Legal Can Collaborate More Effectively” will delve into how to successful integrate alliance management, business development, and the legal division to improve alliance success rates.  They return to the stage for this year’s ASAP BioPharma Conference Sept. 7-9 “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed” at the Revere Hotel, Boston Common, Boston.

 

An alliance strategy consultant, professor at Brandeis University in Waltham, Mass., and author, Gomes-Casseres will be moderating the session with Bayer award-winning cross-functional team of John A. Calvo, Karen Denton, CA-AM, and Claudia Karnbach problem-solving an alliance management case. Attendees will be participants, too, tackling tricky alliance scenarios with best practices through dynamic peer-to-peer exchanges. I asked Gomes-Casseres a few questions about the impetus for the session.

 

What are the most common reasons for the high failure rate of alliances?

As a community, we have made great strides in alliance management, but we have been myopic. We need to broaden our view so that we can see more clearly the faults in alliance strategy and design that frequently lead to dissolution.

The reason half of all alliances fail can be largely attributed to poor up-front design, which includes: 

  • Choosing the wrong partner
  • Deciding to partner for the wrong reasons
  • Flawed contract terms

Part of the problem is that alliance management is left out of the early decision process. Part of it also is that alliance management, business development, and legal speak different languages and concerns. Making a robust alliance requires effective collaboration between business development, legal, and alliance management. However, this aspect of internal collaboration often receives less attention from alliance managers than the work they perform after the deal is “done.” That’s one component in critical need of change to improve the success rate.

What solutions will you and the Bayer panel be recommending in your session? 

At the 2015 BioPharma Conference last year, I held a session with Bayer Healthcare executives from alliance management, business development, and the legal division that focused on four areas: 

  • How Bayer’s does the “Deal to Alliance” process, which is a way of describing how to pay attention to both alliance strategy and management
  • The importance of involving alliance management early on in the deal
  • The contributions alliance management makes to negotiation and contract terms
  • How combining these elements builds more robust alliances

This year, I invited the same team that provided a session at the BioPharma Conference last year to come back and work in an interactive continuation of that session with participants. We plan to quickly rehash what was covered last year and then do a deep dive into fresh and innovative approaches. We plan to share a case study and explore in open discussion how to solve it. In the process, participants will learn how alliance management can contribute to business development and contracting and the best way to bring the D2A process back to their own companies.

 What is your goal of the session for participants?

 The goal is simple but essential to having a solid alliance. We want to:

  • Make more robust and quicker alliances
  • Resolve the differences of perspective among functions in alliance design
  • Broaden the role of alliance management in the organization

How does your new book Remix Strategy: The Three Laws of Business Combinations, published by Harvard Business Review Press, promote some of these ideas?

 Remix Strategy provides the tools to fix this problem. The solution lies in designing alliances so that they can be governed effectively to create value. I call it the “Deal to Alliance” process, which means paying attention to both alliance strategy and management. For a healthy alliance, it’s critical to integrate the process of designing and implementing alliances along their full lifecycle.

Tags:  alliance management  alliances  ASAP BioPharma Conference  Bayer HealthCare  Ben Gomes-Casseres  business development  Claudia Karnbach  collaboration  John A. Calvo  Karen Denton  Keywords: Remix Strategy  management  patner  strategy 

Share |
PermalinkComments (0)
 

Keynote Speaker “Dr. Sam” To Prescribe More Collaboration as Part of the Cure for US Heathcare Ailments at ASAP’s BioPharma Conference

Posted By Cynthia B. Hanson, Tuesday, August 30, 2016
Updated: Saturday, August 27, 2016

He’s a respected medical officer as well as a major mover and shaker in the area of healthcare reform. To those who know him personally, however, Dr. Sam Nussbaum is the wise and approachable “Dr. Sam.” The distinguished healthcare policy expert will be up on the podium at ASAP’s 2016 BioPharma Conference diagnosing woes and handing out prescriptions in relation to the changing political and healthcare scene in his talk “Healing the U.S. Health Care System: Collaboration is Essential” Wednesday, Sept. 7 at the conference “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed” at the Revere Hotel, Boston Common, Boston.

 

As a strategic consultant at EGB Advisors, Inc., the consulting arm for Epstein, Becker & Green, he advises healthcare, life science companies, physicians, hospitals, and provider organizations. He also served as the former executive vice president, clinical health policy, and chief medical officer at Anthem Health from 2000 to 2016, where he was acted as the key spokesperson and policy advocate and oversaw clinical strategy and corporate medical and pharmacy policy. He was responsible for HealthCore, Anthem's clinical outcomes research subsidiary, and helped create the model for the Food and Drug Administration’s Safety Sentinel System. Recognized by Modern Healthcare as one of the "50 Most Influential Physician Executives in Healthcare," he received the 2004 Physician Executive Award of Excellence from the American College of Physician Executives.

"Sam is the ‘advisor to healthcare advisors,’” says Brooke Paige, staff vice president, strategic initiatives at HealthCore, Inc. “He is sure to bring a dynamic energy and unique perspective to the ASAP Biopharma Conference. Sam is a true clinician, always keeping the patient in mind. As we talk about how our healthcare landscape may change in response to the upcoming presidential election, “Dr. Sam” can advise what potential election outcomes could mean for each segment of the industry."

 

Nussbaum is known for his exceptional role in creating collaborative solutions between Anthem, HealthCore, hospital systems, the FDA, and public agencies. He is well-versed in the value of partnering to solve systemic problems at the highest of levels, having helped design and promote patient-centered medical homes and assessed their impact on the quality and cost effectiveness of care. Under his leadership, HealthCore has built partnerships with federal agencies and academic institutions to advance drug safety, comparative effectiveness, and outcomes research.

“Dr. Nussbaum is uniquely qualified to discuss collaborative approaches and help attendees define ecosystem problems specific to their business while envisioning strategic partnering options to best address an alliance challenge,” says ASAP CEO Mike Leonetti, CSAP, of the choice. “We know as partnership professionals, that the US healthcare system will never be fixed without a collaborative approachit's just too complex not to bring the payors, providers, industry, and government participants together.  In addition, Nussbaum is a policy guru with strong healthcare policy experience and can help attendees prepare for a range of potential scenarios stemming from evolving healthcare policy impacted by the presidential elections.”

 

While serving at chief medical officer at WellPoint, he was accountable for $100 billion in healthcare expendituresfrom clinical pharmacy programs to care and disease management. The HealthCore subsidiary built partnerships during that time to further outcomes research, drug safety, and comparative effectiveness with large federal agencies, such as the Centers for Disease Control and FDA, as well as academic institutions.

 

He received his medical degree from Mount Sinai School of Medicine, and trained in internal medicine at Stanford University Medical Center and Massachusetts General Hospital. He also trained in endocrinology and metabolism at Harvard Medical School and Massachusetts General Hospital. He currently serves on the Board of Directors of the OASIS Institute, NEHI, BioCrossroads (an Indiana-based public-private collaboration that advances and invests in the life sciences), and America's Agenda. He is a member of the Scientific Advisory Board of Medidata, a publicly traded clinical technology company serving life sciences clients, and the Healthcare Advisory Board of KPMG. He serves as Chair of the Centers for Education & Research on Therapeutics (CERTs) Steering Committee (a cooperative agreement between AHRQ and the FDA), is a member the HHS Health Care Payment Learning and Action Network (LAN) Guiding Committee, and participates in Institute of Medicine activities, including serving on the Roundtable on Value & Science-Driven Health Care.

 

For more information about the 2016 ASAP BioPharma Conference and keynote speaker Sam Nussbaum, go to http://www.asapweb.org/biopharma/.

Tags:  Anthem Health  ASAP BioPharma Conference  collaborative solutions  Dr. Sam Nussbaum  EGB Advisors  FDA  healthcare  HealthCore  hospital systems  Inc.  life science companies  partnerships  public agencies  WellPoint 

Share |
PermalinkComments (0)
 

New Offerings at ASAP BioPharma Conference Address Wide-ranging Impacts on the Healthcare and Life Sciences Industries

Posted By Cynthia B. Hanson, Saturday, August 27, 2016

As futuristic technologies become realities, professionals in the life sciences and healthcare industries are consulting their maps and charts to determine how their companies should navigate the new waters. Attendees at ASAP’s next BioPharma Conference will have an opportunity to collectively view the vast possibilities at “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed,” Sept. 7-9 at the Revere Hotel in Boston, Mass., USA. This year’s conference will address wide-ranging impacts on the industry, including the changing political scene, multi-partnering, the Internet of Things, and assistive technologies. 

 

After a rich offering of workshops on Sept. 7, the conference will kick off with a timely address from keynote speaker Dr. Sam Nussbaum, strategic consultant, EGB Advisors, Inc., who will present a talk on “Healing the U.S. Health Care System: Collaboration is Essential” (for more information about Nussbaum, see the link in this E-news), followed by a networking opportunity. The following two days include a plenary and about 26 forward-thinking, thought-provoking sessions from which to choose.

 

"The ASAP Biopharma Conference is a must-attend for alliance professionals of all experience levels,” says Jan Twombly, CSAP, former ASAP chairman of programming, and president of The Rhythm of Business. “It traditionally offers equal parts of looking outward to how the industry is changing and the implications for managing the risk and optimizing the value of alliances and other collaborations, as well as looking inward to develop the mindset, skillset, and toolset of a modern alliance capability.”

 

Well-known and respected industry luminaries are unveiling some never-before-presented information and perspectives. Take, for example, these insightful offerings:

  •  “Applying the Latest Alliance Management Research to Your Partnering Practice,” presented by Stuart Kliman, CA-AM, partner, alliance practice leader at Vantage Partners, and Shawn Wilson, DBA, vice president and general manager at Beaulieu Group: Two new groundbreaking research studies provide critical data on current trends, challenges, and opportunities in the alliance management profession.
  • “A New Model for Western and Chinese Pharmaceutical Partnering,” presented by Brent Harvey, CA-AM, director of Alliances, Eli Lilly and Company: "How To" insights on collaboration drawn from a longstanding, advanced partnership model between Eli Lilly and Company and WuXi AppTech, which provides, among other things, examples of how to leverage the regulatory environment in China to bring new drugs to market faster.
  • “New Partnerships between High Tech and BioPharma and the Alliance Management Practices to Support Them,” presented by Russ Buchanan, CSAP head of corporate alliances at Xerox Corporation, Joseph Schramm, VP strategic alliances at BeyondTrust, and David Thompson, CA-AM chief alliance officer at Eli Lilly and Company: Key insights provided by two highly accomplished technology company alliance executives that are sure to generate discussion about how biopharma alliance professionals can overcome potential challenges when partnering with tech companies.

 Preparing for rapid change is a central theme throughout the conference, and some of the workshops are offering essential “updates” for the alliance management toolbox. “With many more partners for many more purposes, new partnering models and differences to leverage, no alliance manager can rest on his or her laurels,” points out Twombly. “Unique among biopharma alliance management conferences, the ASAP Biopharma Conference leans in on where the profession is going, not where it has been."

 

Several workshops being offered emphasize the need to stay abreast of pressing industry changes, such as “Next Generation Alliance Management, Lean and Agile” facilitated by Lynda McDermott, CA-AM, president of EquiPro International, and Annick De Swaef, CSAP, managing partner of Consensa Consulting. Their workshop addresses digitalization’s influence on biopharma and cross-industry partnering, and it centers around basic questions that everyone in the industry is asking: “Are my team's current alliance best practices future proof? Should my alliance team acquire new skills?” De Swaef recommends combining ASAP’s newly launched in-company team training with the CA-AM Certification Exam Prep to strengthen company capabilities, expand into new areas of value creation, and introduce new best practices.

 

Twombly and Rhythm of Business Principal, Jeff Shuman, CSAP, are offering their own forward-thinking, 90-minute, hands-on workshop on design thinking for complex problems, such as for multi-partnering, non-asset-base alliances, and partnering with “sectors who run on much faster clock speeds than is typically seen in biopharma.” The data-driven, user experience-centered innovation and problem-solving methodology has been adapted for alliances and partnering practices.

 ASAP also plans to unveil a new custom-designed session: The ASAP Aquarium, facilitated by Twombly. Similar to a “fishbowl” communications activity, where the line is intentionally blurred between listeners and participants, ASAP’s version will start off with a deep discussion between industry thought leaders and senior-level partnering executives as the audience gazes into the aquarium. Listeners will then be able to “tap in,” join the discussion with a hot idea or new perspective, and replace the initial participants. The session provides for a fun way to actively engage and contribute to the collective wisdom of the group while exploring the questions that matter most as alliance professionals “engage with new faces and in unexpected places.”

Tags:  Alliance Professionals  Annick De Swaef  ASAP BioPharma Conference  BeyondTrust  Brent Harvey  collaboration  David Thompson  Dr. Sam Nussbaum  Eli Lilly and Company  EquiPro International  Jan Twombly  Jeff Shuman  Joseph Schramm  Lynda McDermott  Russ Buchanan  The Rhythm of Business  WuXi AppTech  Xerox 

Share |
PermalinkComments (0)
 

Q3 2015 Strategic Alliance Magazine: Alliance Leaders Make the Paradigm Shift to Cross-Industry and Ecosystem Partnering, Plus Partnering in the Channel and More

Posted By Cynthia B. Hanson, Thursday, September 24, 2015

The latest issue of Strategic Alliance Magazine, Q3 2015, now available to ASAP members, invites readers to explore a paradigm shift occurring in the life sciences and healthcare industries (and many others too). Veteran alliance executives discuss how to adapt, lead, and orchestrate in new and innovative ways, as cross-industry collaborations proliferate thanks to high tech and other industries entering the traditional biopharma and healthcare arena. Alliance managers are challenged to read the tea leaves and adapt to customer-centric trends and other drivers forcing change.

 

SAM Q3 2015 also provides a preview of the 2015 ASAP BioPharma Conference that took place in Boston Sept. 9-11 “Alliance Expertise at the Forefront: Leadership for the Ecosystem.” Highlights include the opening evening keynote on the analytics-driven innovative partnerships Boston-based Berg Pharmaceuticals has formed with research hospitals, as well as three “ASAP Quick Takes” given by IBM Institute for Business Value's Heather Fraser, Janssen Pharmaceutical Companies of Johnson & Johnson’s Cindy Warren, and the Alzheimer’s Association’s Lenore Jackson-Pope. The talks were preceded by professional development workshops and followed by a rich selection of educational sessions.

 

In our quarterly Alliance Champion feature, I interviewed Leona Kral, CSAP, of Verizon, who offered insights on driving revenue in channel management. Adaptation, agility, and innovation are critical components for alliance managers dealing with a fluid business environment, and that requires a wardrobe of hats alliance managers can wear to compliment their changing roles, she advises. Kral joined with her Verizon colleague Karen Robinson, CSAP, to present ASAP’s September Netcast Webinar, “What in the World are Two Alliance Professionals Doing in the Channel?” available for viewing in the ASAP Member Resource Library.

 

Continuing in the same vein of exploring the challenges (and opportunities) in channel sales partnerships, Dede Haas, CA-AM, founder and president of DLH Services, outlines the problems that make channel partners unhappy with vendors, and then offers practical advice from experienced channel executives on how to improve such collaborations through trust-based relationships.

 

The magazine also spotlighted how corporate member Dassault Systèmes and its partners use three-dimensional visualization technologies and collaborative tools—in the process changing the way business is being done in industries ranging from manufacturing and high tech to architecture and engineering, as well as in the public sector.

 

In the magazine’s quarterly editorial supplement, sponsored by Eli Lilly and Company, Michael Berglund, CA-AM and David Thompson, CA-AM, explore the powerful impact of the “conviction curve” on whether or not decision-making processes are actually collaborative. Berglund also delved into the topic in his well-attended workshop at this month’s ASAP BioPharma Conference, honing in on the crucial distinction of “Are We Negotiating or Collaborating?”

 

“Are you ready to thrive at the center of the action?” asks executive publisher and ASAP President and CEO Michael Leonetti, CSAP, in his engaging Up Front editorial. Alliances are taking new forms as partnering proliferates across the new ecosystem, and this issue of Strategic Alliance Magazine appropriately points out that alliance management needs to be embedded and is an essential component to the culture of today’s business enterprises if they are to adapt and proliferate in the emerging ecosystem.

Tags:  alliance  ASAP BioPharma Conference  Cindy Warren  collaboration  Dassault Systèmes  David Thompson  Dede Haas  ecosystem  Heather Fraser  Karen Robinson  Lenore Jackson-Pope  Leona Kral.ASAP Netcast Webinar  Michael Berglund  Strategic Alliance Magazine 

Share |
PermalinkComments (0)
 
Page 2 of 3
1  |  2  |  3
For more information email us at info@strategic-alliances.org or call +1-781-562-1630